摘要
目的观察阿德福韦酯片(商品名贺维力)联合双环醇片(商品名百赛诺)治疗慢性乙型肝炎(CHB)的临床疗效。方法将60例CHB患者按就诊顺序随机分为治疗组和对照组2组,每组各30例。治疗组患者每日口服贺维力10 mg(1次/d)、百赛诺25 mg(3次/d);对照组患者每日仅口服贺维力10 mg(1次/d);两组均连续用药48周。治疗前、治疗24周后、治疗48周后两组患者丙氨酸转氨酶(ALT)、尿素氮(BUN)、肌酐Cr水平比较采用t检验;治疗24周后、治疗48周后两组患者ALT复常率、HBV DNA转阴率比较采用χ2检验。结果治疗24周后治疗组患者ALT水平为(145.47±61.95)U/L,较对照组的(189.09±52.02)下降,且差异有统计学意义(t=2.953,P=0.005);同时治疗组ALT复常率高于对照组,差异也有统计学意义[80.0%(24/30)与43.3%(13/30)比较,χ2=7.051,P=0.008];但两组患者HBV DNA转阴率差异无统计学意义[50.0%(15/30)与43.3%(13/30)比较,χ2=0.067,P=0.796]。治疗48周后治疗组ALT水平低于对照组[(91.38±48.98)U/L与(60.03±29.89)U/L比较],而ALT复常率、HBV DNA转阴率均高于对照组[63.3%(19/30)与90.0%(27/30)比较,73.3%(22/30)与53.3%(16/30)比较],且差异均有统计学意义(t=2.515,P=0.015;χ2=4.565,P=0.033;χ2=4.800,P=0.029)。治疗24周后、治疗48周后两组患者肾功能指标(BUN、Cr水平)与治疗前比较均无明显改变,且差异均无统计学意义。两组患者在治疗过程中均未发现明显不良反应。结论贺维力联合百赛诺治疗CHB能取得更好的生化学应答和病毒学应答,且安全性好。
Objective To analyze the effect of adefovir dipivoxil combined with bicyclol in the treatment of chronic viral hepatitis B （ CHB ）. Methods Sixty patients with CHB were randomly divided into two groups ： the treatment group （30 cases） and the control group （30 cases）. Thirty patients in the treatment group orally received adefovir dipivoxil（ 10 rag,once a day）and bicyclol（25 rag, two times a day） for 48 weeks. Thirty control subjects received adefovir dipivoxil （ 10 rag, once a day）orally for 48 weeks. The level of serum aminotransferace （ ALT）, blood urea nitrogen （ BUN ） and creatinine （Cr） of patients with pre-treatments ,24 weeks post-treatments and 48 weeks post-treatments between the two groups were compared with t-test. The ALT level normalization rates and HBV DNA negative rates of patients with 24 weeks post-treatments and 48 weeks post-treatments between the two groups were compared with X2-test. Results The ALT level of patients in the treatment group 24 weeks post-treatment were lower than that of the control group [ （145.47 ±61.95 ）U/L vs （189.09 ±52.02）U/L]. And the difference was statistically significant（t = 2. 953, P = 0. 005 ）. Twenty-four weeks after treatment, the ALT level of patients in the treatment group was lower than that in the control group, while the ALT level normalization rates in the treatment group was higher than that in the control group[43.3% （13/30） vs 80.0% （24/30） ]. And the X2 differences were both statistically significant （ t = 2. 953, P = 0. 005 ; = 7.051, P = 0.008 ） The differences of HBV DNA negative rates of the two groups was not statistically significant 24 weeks post-treatments. Forty-eight weeks after treatment, the ALT level of patients in the treatment group was lower than that in the control group [ （ 60.03 ± 29.89 ） U/L vs （91.38 ±48.98 ） U/L ], while the ALT level normalization rates and HBV DNA negative rates of patients in the treatment group was higher than that in the control group [73.3% （22/30） vs 53. 3% （16/30）, 63. 3% （19/30） vs 90.0% （27/30）]. And the differences were all statistically significant（t =2. 515,P =0. 015; X2 =4. 565,P =0. 033; X2 =4. 800,P =0. 029）. The differences of the BUN level and Cr level of the two groups 24 or 48 weeks post-treatments were not statistically significant compared with that of pre-treatments. The two groups of patients were not found significant adverse reactions during treatment. Conclusion The treatment of adefovir dipivoxil combined with Bicyclol would get better biochemical response and virological responseis, and has good security.
出处
《中华消化病与影像杂志（电子版）》
2012年第6期26-29,共4页
Chinese Journal of Digestion and Medical Imageology(Electronic Edition)
关键词
慢性乙型肝炎
阿德福韦酯
双环醇
治疗结果
Chronic hepatitis B
Adefovir dipivoxil
Bicyclol
Treatment outcomes
